Dialysis keeps hundreds of thousands of people alive every year, but the treatment carries a heavy toll. Fewer than four in ten patients survive beyond five years, and the threat of infection hangs over every session. Despite being a $50 billion industry, dialysis remains largely invisible to the public — a quiet corner of medicine where life and death are routine.
The survival reality
For patients with kidney failure, dialysis is a life-saving intervention. Yet the numbers are stark: less than 40% of those who start dialysis will be alive five years later. That survival rate is lower than many cancers. The treatment buys time but not a cure. Patients often spend hours hooked to a machine three times a week, and the underlying disease — plus the stress on the body — takes a steady toll.
Infection risks that won't go away
Dialysis requires direct access to the bloodstream, either through a catheter, graft, or fistula. Each connection point is a potential entry for bacteria. Infections — from local site infections to life-threatening sepsis — are a persistent hazard. Despite strict protocols, bloodstream infections remain a leading cause of hospitalization and death among dialysis patients. The industry has invested in better hygiene and new technologies, but the risk is built into the procedure itself.
A $50 billion industry that stays out of sight
Dialysis is big business. The global market is worth roughly $50 billion, driven by two large providers that dominate outpatient care in the United States and many other countries. Yet most people never see a dialysis center. They're tucked into strip malls, hospital basements, or standalone buildings with no signage. The treatment is expensive — Medicare alone spends billions each year — but the public rarely discusses it. Kidney disease affects millions, but dialysis doesn't get the attention of heart disease or cancer.
What’s next for patients and providers
Regulators and insurers are pushing for more home dialysis and kidney transplants, both of which offer better survival and quality of life. But the infrastructure and training for home dialysis lag behind. The industry is also under pressure to reduce infection rates, with new reimbursement penalties tied to hospital readmissions and bloodstream infections. Whether those measures will move the survival needle remains an open question.
